Onesource Specialty Pharma Limited has informed the Exchange about Amalgamation/Merger
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
On September 26, 2025, the Board of OneSource Specialty Pharma approved a composite scheme to merge four related entities into itself: Steriscience Specialties (SSPL), Brooks Steriscience (BSL), Steriscience Pte Singapore, and Strides Pharma Services (SPSPL, a wholly-owned subsidiary). BSL, a Carbapenem antibiotic manufacturer with FY25 turnover of about ₹40 crore, and Steriscience SG (Singapore-based CDMO with about ₹235 crore turnover) will be the main value-adding entities. The deal is share-based with no cash payout — 137 OneSource shares for every 10 BSL shares, and 53 OneSource shares for every 100 Steriscience SG shares. The scheme also includes a financial restructuring to set off OneSource's negative retained earnings against its securities premium account to clean up the balance sheet. The deal is between entities with common promoters, so it is a related-party transaction requiring shareholder, NCLT, SEBI, and Singapore Court approvals.
If approved, OneSource will become a larger multi-modality CDMO platform with a European footprint, but existing public shareholders will see dilution from 70.23% to 63.83% as promoter stake rises to 36.17%. The merger could boost long-term value through synergies and scale, but execution risk and regulatory approvals remain key milestones to watch.